Table 4.
Sensitivity Analysis for Risk of Coronary Heart Disease per 1.03-mmol/L Increase in Total Cholesterol and LDL Cholesterol Levels, According to hs-CRP Category at Visit 4 (1996–1997), Atherosclerosis Risk in Communities Study, United States, 1987–2008a
| hs-CRP Level |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age <65 Years |
Age ≥65 Years |
|||||||||||
| <2 mg/L (n = 2,483) |
≥2 mg/L (n = 3,146) |
Overall (n = 5,629) |
<2 mg/L (n = 1,446) |
≥2 mg/L (n = 1,872) |
Overall (n = 3,318) |
|||||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Total cholesterol | ||||||||||||
| Sex | ||||||||||||
| Male | 1.37 | 1.14, 1.63 | 1.39 | 1.17, 1.62 | 1.38 | 1.22, 1.56 | 1.40 | 1.14, 1.71 | 1.32 | 1.11, 1.57 | 1.36 | 1.20, 1.55 |
| Female | 1.45 | 1.11, 1.92 | 1.37 | 1.17, 1.60 | 1.40 | 1.22, 1.60 | 1.61 | 1.22, 2.12 | 0.98*,** | 0.81, 1.18 | 1.13** | 0.97, 1.32 |
| Race | ||||||||||||
| White | 1.38 | 1.06, 1.63 | 1.30 | 1.34, 1.82 | 1.33 | 1.20, 1.48 | 1.43 | 1.20, 1.71 | 1.21 | 1.05, 1.40 | 1.38 | 1.19, 1.60 |
| Black | 1.49 | 1.10, 2.02 | 1.70 | 1.33, 2.16 | 1.59 | 1.32, 1.92 | 1.55 | 1.04, 2.32 | 0.94*,** | 0.71, 1.24 | 1.11 | 0.89, 1.40 |
| Diabetes | ||||||||||||
| Yes | 1.43 | 1.08, 1.90 | 1.48 | 1.17, 1.88 | 1.48 | 1.24, 1.78 | 1.44 | 1.01, 2.06 | 1.03** | 0.80, 1.32 | 1.14 | 0.93, 1.39 |
| No | 1.36 | 1.14, 1.63 | 1.34 | 1.18, 1.53 | 1.36 | 1.22, 1.51 | 1.49 | 1.25, 1.79 | 1.18* | 1.02, 1.36 | 1.30 | 1.16, 1.46 |
| Years of follow-up | ||||||||||||
| 0–5 | 1.32 | 1.06, 1.63 | 1.56 | 1.34, 1.82 | 1.48 | 1.31, 1.69 | 1.52 | 1.19, 1.93 | 1.28 | 1.06, 1.54 | 1.38 | 1.19, 1.60 |
| >5–10 | 1.45 | 1.15, 1.82 | 1.09 | 0.89, 1.34 | 1.23 | 1.06, 1.43 | 1.29 | 0.99, 1.68 | 1.02 | 0.84, 1.24 | 1.11 | 0.95, 1.30 |
| hs-CRP level | ||||||||||||
| <10 mg/L | 1.39 | 1.20, 1.61 | 1.26 | 1.11, 1.44 | 1.32 | 1.20, 1.46 | 1.45 | 1.24, 1.71 | 1.17* | 1.02, 1.34 | 1.29 | 1.16, 1.43 |
| No rheumatoid arthritis or lupus | 1.43 | 1.22, 1.67 | 1.35 | 1.20, 1.52 | 1.39 | 1.27, 1.53 | 1.57 | 1.01, 1.32 | 1.27* | 1.15, 1.41 | 1.43 | 1.16, 1.77 |
| LDL cholesterol | ||||||||||||
| Sex | ||||||||||||
| Male | 1.39 | 1.12, 1.71 | 1.41 | 1.17, 1.71 | 1.43 | 1.25, 1.63 | 1.44 | 0.96, 2.15 | 1.32 | 1.09, 1.60 | 1.39 | 1.19, 1.57 |
| Female | 1.42 | 1.05, 1.92 | 1.40 | 1.19, 1.65 | 1.41 | 1.21, 1.63 | 1.42 | 1.17, 1.72 | 1.12*,** | 0.96, 1.32 | 1.00** | 0.88, 1.23 |
| Race | ||||||||||||
| White | 1.41 | 1.17, 1.70 | 1.32 | 1.14, 1.52 | 1.35 | 1.21, 1.52 | 1.39 | 1.15, 1.67 | 1.16 | 0.99, 1.37 | 1.27 | 1.12, 1.43 |
| Black | 1.53 | 1.11, 2.11 | 1.71 | 1.33, 2.21 | 1.62 | 1.33, 1.98 | 1.42 | 0.91, 2.20 | 0.94** | 0.70, 1.27 | 1.08** | 0.84, 1.38 |
| Diabetes | ||||||||||||
| Yes | 1.51 | 1.11, 2.04 | 1.46 | 1.13, 1.89 | 1.50 | 1.23, 1.83 | 1.44 | 1.96, 2.15 | 1.03 | 0.79, 1.35 | 1.13 | 0.91, 1.40 |
| No | 1.39 | 1.15, 1.68 | 1.38 | 1.20, 1.59 | 1.38 | 1.23, 1.54 | 1.42 | 1.17, 1.72 | 1.12 | 0.96, 1.32 | 1.25 | 1.10, 1.42 |
| Years of follow-up | ||||||||||||
| 0–5 | 1.34 | 1.05, 1.70 | 1.60 | 1.36, 1.89 | 1.51 | 1.31, 1.73 | 1.50 | 1.16, 1.96 | 1.20* | 0.98, 1.48 | 1.33 | 1.13, 1.56 |
| >5–10 | 1.50 | 1.18, 1.92 | 1.10 | 0.89, 1.37 | 1.25 | 1.07, 1.47 | 1.18 | 0.89, 1.57 | 1.03 | 0.84, 1.27 | 1.08 | 0.92, 1.28 |
| hs-CRP level | ||||||||||||
| <10 mg/L | 1.43 | 1.21, 1.67 | 1.27 | 1.10, 1.46 | 1.33 | 1.20, 1.48 | 1.41 | 1.18, 1.67 | 1.12 | 0.97, 1.31 | 1.25 | 1.11, 1.40 |
| No rheumatoid arthritis or lupus | 1.38 | 1.21, 1.56 | 1.42 | 1.28, 1.57 | 1.26 | 1.02, 1.55 | 1.11 | 0.96, 1.28 | 1.23 | 1.09, 1.38 | 1.45 | 1.17, 1.80 |
Abbreviations: ARIC, Atherosclerosis Risk in Communities Study; CI, confidence interval; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein.
* P < 0.05 (compared with lower hs-CRP group); ** P < 0.05 (compared with lower age group).
a Results were adjusted for age, sex, race, current smoking, diabetes, hypertension, body mass index, and high-density lipoprotein cholesterol.